NCT06322641View on ClinicalTrials.gov

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

May 10, 2024

Study Completion Date

May 10, 2024

Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)Systemic Inflammation
Interventions
OTHER

No treatment given

No treatment given

Trial Locations (1)

14623

KJT Group, Inc., Rochester

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06322641 - A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists | Biotech Hunter | Biotech Hunter